ClinicalTrials.gg
CompletedNCT04394377ACTIONUpdated Jun 10, 2021

Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial

A Phase 4 interventional study of Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed and Group 2: control group with enoxaparin 40mg/d in Coronavirus Infection, sponsored by Brazilian Clinical Research Institute. Completed at 36 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-10.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Brazilian Clinical Research Institute · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
615
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing rivaroxaban in COVID-19 — none open to participants now, none under way, none of them phase 3. Rivaroxaban · COVID-19.

Enrollment
4th of 11
615 · median 497
Started
2020
with 10 others
Phase 4
3 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
1 of 11
Brazilian Clinical Research Institute

Among the 11 studies testing rivaroxaban in COVID-19, this one is the 4th largest by enrollment, is one of 11 that started in 2020, is one of 3 in phase 4, and was the 4th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 11 studies testing rivaroxaban in COVID-19 is open now. The open studies under COVID-19, anywhere →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing rivaroxaban in COVID-19 as a file.
02

Study summary

Pragmatic randomized clinical trial of patients admitted to the hospital with confirmed COVID-19 infection and elevated D-Dimer.

Randomization 1:1 - Group 1 will undergo a routine full anticoagulation (oral or parenteral when needed) strategy; and group 2 will receive usual standard of care with prophylactic anticoagulation

Read the detailed description

Patients admitted to hospital with confirmed COVID-19, and who meet the eligibility criteria will be invited to participate in the proposed study. Following the application of the informed consent form, they will collect the D-dimer (if they have not yet collected it routinely from the hospital) and confirm the value over the normal limit in patients with confirmed COVID-19, will be randomized to 2 groups in the 1:1 ratio. Group 1 will follow the strategy of routine use of full anticoagulation therapy (oral or parenteral when indicated); and group 2 will follow the usual standard care with in-hospital prophylactic anticoagulation (without routine full anticoagulation).

03

Conditions studied

  • Coronavirus Infection

Browse trials for

Keywords

  • SARS-CoV2
  • Anticoagulation
  • Coronavirus infection
  • COVID-19
04

In context

COVID-19 Reclassified

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

This study's enrollment of 615 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Brazilian Clinical Research Institute is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with confirmed diagnosis of COVID-19 admitted to hospital;
  • Duration of symptoms related to hospitalization ≤ 14 days;
  • Patients ≥ 18 year old;
  • D-dimer above the (collected until 72 hours before the randomization);
  • Agreement to participate by providing the form (ICF).

Exclusion criteria

Exclusion Criteria:

  • Patients with indication for full anticoagulation during inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis);
  • \< 50,000 /mm3
  • Need for ASA therapy > 100 mg;
  • Need for P2Y12 inhibitor therapy (clopidogrel, ticagrelor or prasugrel);
  • Chronic use of non-hormonal anti-inflammatory drugs;
  • Sustained uncontrolled systolic blood pressure (BP) of ≥180 mmHg or diastolic BP of ≥100 mmHg;
  • > 1,5;
  • Patients to full anticoagulation (active bleeding, liver failure, blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator);
  • Criteria for disseminated intravascular coagulation (DIC);
  • A history of hemorrhagic stroke or any intracranial bleeding at any time in the past or current intracranial neoplasm (benign or malignant), cerebral , arteriovenous (AV) malformation, or aneurysm;
  • Active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy;
  • to rivaroxaban;
  • Use of strong inhibitors of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp) (e.g. protease inhibitors, ketoconazole, Itraconazole) and/or use of P-gp and strong inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or St. John's Wort);
  • Known infection;
  • \< 30 ml/min according to the Cockcroft-Gault Formula;
  • Pregnancy or breastfeeding.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
615 participants (actual)

Study arms

  • Other
    Group 1

    The routine full anticoagulation strategy will be applied for 30 days. In this strategy, full anticoagulation therapy will be maintained for all patients randomized to group 1 and, depending on the patient's clinical condition, there will be 2 possible routes of administration (oral or parenteral): * Oral: Rivaroxaban 20 mg 1 x daily (adjust the dose to 15 mg 1x daily if ClCr between 30 and 49ml/min and/or concomitant use of azithromycin); * Parenteral: Enoxaparin 1 mg/kg every 12 hours subcutaneously or Unfractionated heparin (preferable option for patients progressing with disseminated intravascular coagulation).

    Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed

  • Other
    Group 2

    Patients in this group will receive the usual standard management and currently have no indication of full anticoagulation. Venous thromboembolism (VTE) prophylaxis should be used in group 2 (usual standard of care) as recommended by guidelines.

    Drug: Group 2: control group with enoxaparin 40mg/d

Interventions

  • DrugGroup 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed

    Drug page: RivaroxabanStudies of RivaroxabanRivaroxaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Routine full anticoagulation strategy

  • DrugGroup 2: control group with enoxaparin 40mg/d

    Usual standard of care and currently have no indication of full anticoagulation.

07

What researchers measure

Primary outcomes

  1. Hierarchical composite endpoint composed of mortality, number of days alive, number of days in the hospital and number of days with oxygen therapy at the end of 30 days.

    The primary objective will be analyzed using the win ratio approach comparing every participant of treatment group to every participant of control group to determine a winner.

    Time frame: In 30 days

Secondary outcomes

  1. Incidence of Venous thromboembolism

    Time frame: In 30 days

  2. Incidence of acute myocardial infarction

    Time frame: In 30 days

  3. Incidence of stroke

    Time frame: In 30 days

  4. Number of days using oxygen therapy

    Time frame: In 30 days

  5. Peak of troponin

    Time frame: In 30 days

  6. Peak of D-dimer

    Time frame: In 30 days

  7. Incidence of Major bleeding and clinically relevant non-major bleeding by the ISTH criteria

    It will be considered the main safety endpoint

    Time frame: In 30 days

08

Study locations

36 sites
  • Centro de Estudos Clínicos do Hospital Cárdio Pulmonar
    Salvador, Bahia, Brazil
  • Instituto de Ensino e Pesquisa do Hospital da Bahia
    Salvador, Bahia, Brazil
  • Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel
    Salvador, Bahia, Brazil
  • Hospital Maternidade São Vicente de Paulo
    Barbalha, Ceará, Brazil
  • Centro de Ensino e Aperfeiçoamento em Pesquisa - CEAP
    Serra, Espirito Santo, Brazil
  • Centro de Pesquisas Cardiológicas de Goiânia do Hospital das Clínicas (UFG)
    Goiânia, Goiás, Brazil
  • Hospital Vera Cruz
    Belo Horizonte, Minas Gerais, Brazil
  • Núcleo de Ciências de Saúde - Unidade de Pesquisa - Hospital Felício Rocho
    Belo Horizonte, Minas Gerais, Brazil
  • Centro de Pesquisa Clínica do Hospital de Clínicas da Universidade Federal de Uberlândia
    Uberlândia, Minas Gerais, Brazil
  • Hospital Universitário da Universidade Estadual de Londrina
    Londrina, Paraná, Brazil
  • Hospital Agamenon Magalhães
    Recife, Pernambuco, Brazil
  • Real Hospital Português de Beneficência em Pernambuco
    Recife, Pernambuco, Brazil
  • Hospital Moinhos de Vento
    Porto Alegre, Rio Grande Do Sul, Brazil
  • Hospital Nereu Ramos
    Florianópolis, Santa Catarina, Brazil
  • Instituto Baia Sul de Ensino E Pesquisa Dr. Irineu May Brodbeck / Hospital Baía Sul
    Florianópolis, Santa Catarina, Brazil
  • Hospital Regional Hans Dieter Schmidt
    Joinville, Santa Catarina, Brazil
  • Hospital de Amor de Barretos - (Pio XII)
    Barretos, São Paulo, Brazil
  • Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - Unesp
    Botucatu, São Paulo, Brazil
  • Hospital Universitário São Francisco de Assis
    Bragança Paulista, São Paulo, Brazil
  • Hospital Regional do Litoral Norte
    Caraguatatuba, São Paulo, Brazil
  • Hospital Regional de Registro
    Registro, São Paulo, Brazil
  • Praxis Pesquisa Médica
    Santo André, São Paulo, Brazil
  • Centro Integrado de Pesquisa (CIP) - Hospital de Base de Rio Preto
    São José Do Rio Preto, São Paulo, Brazil
  • Hospital Regional de São José dos Campos
    São José Dos Campos, São Paulo, Brazil
  • Santa Casa de Misericórdia de Votuporanga
    Votuporanga, São Paulo, Brazil
  • Hospital Naval Marcílio Dias
    Rio de Janeiro, Brazil
  • BP - A Beneficência Portuguesa de São Paulo
    São Paulo, Brazil
  • Hcor - Hospital do Coração
    São Paulo, Brazil
  • Hospital Israelita Albert Einstein
    São Paulo, Brazil
  • Hospital Moriah
    São Paulo, Brazil
  • Hospital Samaritano Paulista
    São Paulo, Brazil
  • Hospital Santa Paula
    São Paulo, Brazil
  • Hospital São Paulo
    São Paulo, Brazil
  • Instituto Dante Pazzanese de Cardiologia
    São Paulo, Brazil
  • Instituto de Assistência Médica ao Servidor Público Estadual de S. Paulo
    São Paulo, Brazil
  • Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP-InCor-HCFMUSP
    São Paulo, Brazil
09

References and documents

Publications

  • Flumignan RL, Civile VT, Tinoco JDS, Pascoal PI, Areias LL, Matar CF, Tendal B, Trevisani VF, Atallah AN, Nakano LC. Anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2022 Mar 4;3(3):CD013739. doi: 10.1002/14651858.CD013739.pub2. PubMed 35244208 ↗
  • Lopes RD, de Barros E Silva PGM, Furtado RHM, Macedo AVS, Bronhara B, Damiani LP, Barbosa LM, de Aveiro Morata J, Ramacciotti E, de Aquino Martins P, de Oliveira AL, Nunes VS, Ritt LEF, Rocha AT, Tramujas L, Santos SV, Diaz DRA, Viana LS, Melro LMG, de Alcantara Chaud MS, Figueiredo EL, Neuenschwander FC, Dracoulakis MDA, Lima RGSD, de Souza Dantas VC, Fernandes ACS, Gebara OCE, Hernandes ME, Queiroz DAR, Veiga VC, Canesin MF, de Faria LM, Feitosa-Filho GS, Gazzana MB, Liporace IL, de Oliveira Twardowsky A, Maia LN, Machado FR, de Matos Soeiro A, Conceicao-Souza GE, Armaganijan L, Guimaraes PO, Rosa RG, Azevedo LCP, Alexander JH, Avezum A, Cavalcanti AB, Berwanger O; ACTION Coalition COVID-19 Brazil IV Investigators. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021 Jun 12;397(10291):2253-2263. doi: 10.1016/S0140-6736(21)01203-4. Epub 2021 Jun 4. PubMed 34097856 ↗
  • Lopes RD, de Barros E Silva PGM, Furtado RHM, Macedo AVS, Ramacciotti E, Damini LP, Bronhara B, Cavalcanti AB, Rosa RG, Azevedo LCP, Veiga VC, Machado FR, Ritt LE, Martins PA, Alexander JH, Avezum A, Berwanger O; Coalition COVID-19 Brazil IV Investigators. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial. Am Heart J. 2021 Aug;238:1-11. doi: 10.1016/j.ahj.2021.04.005. Epub 2021 Apr 20. PubMed 33891907 ↗
  • Flumignan RL, Tinoco JDS, Pascoal PI, Areias LL, Cossi MS, Fernandes MI, Costa IK, Souza L, Matar CF, Tendal B, Trevisani VF, Atallah AN, Nakano LC. Prophylactic anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2020 Oct 2;10(10):CD013739. doi: 10.1002/14651858.CD013739. PubMed 33502773 ↗

Individual participant data

Plan to share: Yes — All data provided during study is anonymized to respect the privacy of patients who have participated in the trial in line with applicable regulations.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Mar 2021, 9 months.

Of 145 non-industry phase 4 interventional studies under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 9 months is close to that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2020
First posted
May 19, 2020
StartActual
Jun 21, 2020
Primary completionActual
Mar 26, 2021
CompletionActual
May 30, 2021
Last update
Jun 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04394377
Lead sponsor
Brazilian Clinical Research Institute
Collaborators
Hospital Israelita Albert Einstein, Hospital do Coracao, Hospital Sirio-Libanes, Hospital Moinhos de Vento, Hospital Alemão Oswaldo Cruz, Beneficência Portuguesa de São Paulo, Brazilian Research In Intensive Care Network
Responsible party
Sponsor
First posted
May 19, 2020
Start date
Jun 21, 2020
Primary completion
Mar 26, 2021
Completion
May 30, 2021
Last update
Jun 10, 2021

Study contacts

Renato D. Lopes, MD, PhD
study chair · BCRI

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion